Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (141-150 of 442) with videos related to

Pageof 45
Sort By:
British Journal of Cancer|September 2, 2020
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trialsJohnique T Atkins, Goldy C George, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant AccrualChad Tang, Kenneth R Hess, Dwana Sanders, et al.
The Journal of Craniofacial Surgery|January 17, 2025
Success of Bone Ossification After Posterior Vault Distraction Osteogenesis in Patients With CraniosynostosisJamasb J Sayadi, Jorge Lujan-Hernandez, Kevin B Givechian, et al.
The Journal of Craniofacial Surgery|July 2, 2019
Topical Vancomycin for Surgical Prophylaxis in Pediatric Craniofacial SurgeriesJyodi Mohole, Allen L Ho, John G D Cannon, et al.
Clinical Colorectal Cancer|January 7, 2011
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastasesLuis H Camacho, Sheila Garcia, Amar M Panchal, et al.
International Journal of Dermatology|July 25, 2013
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactionsJonathan L Curry, Carlos A Torres-Cabala, Kevin B Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2020
Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?Uri Greenbaum, Fevzi F Yalniz, Samer A Srour, et al.
Investigational New Drugs|January 31, 2013
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignanciesAung Naing, Roger Cohen, Grace K Dy, et al.
Cancer|August 9, 2011
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna, Filip Janku, Christos Vaklavas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumorsAung Naing, Patricia LoRusso, Siqing Fu, et al.
Pageof 45

Showing results (141-150 of 442) with videos related to

Sort By:
Pageof 45
British Journal of Cancer|September 2, 2020
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trialsJohnique T Atkins, Goldy C George, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant AccrualChad Tang, Kenneth R Hess, Dwana Sanders, et al.
The Journal of Craniofacial Surgery|January 17, 2025
Success of Bone Ossification After Posterior Vault Distraction Osteogenesis in Patients With CraniosynostosisJamasb J Sayadi, Jorge Lujan-Hernandez, Kevin B Givechian, et al.
The Journal of Craniofacial Surgery|July 2, 2019
Topical Vancomycin for Surgical Prophylaxis in Pediatric Craniofacial SurgeriesJyodi Mohole, Allen L Ho, John G D Cannon, et al.
Clinical Colorectal Cancer|January 7, 2011
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastasesLuis H Camacho, Sheila Garcia, Amar M Panchal, et al.
International Journal of Dermatology|July 25, 2013
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactionsJonathan L Curry, Carlos A Torres-Cabala, Kevin B Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2020
Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?Uri Greenbaum, Fevzi F Yalniz, Samer A Srour, et al.
Investigational New Drugs|January 31, 2013
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignanciesAung Naing, Roger Cohen, Grace K Dy, et al.
Cancer|August 9, 2011
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna, Filip Janku, Christos Vaklavas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumorsAung Naing, Patricia LoRusso, Siqing Fu, et al.
Pageof 45